JPWO2020247618A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020247618A5 JPWO2020247618A5 JP2021571870A JP2021571870A JPWO2020247618A5 JP WO2020247618 A5 JPWO2020247618 A5 JP WO2020247618A5 JP 2021571870 A JP2021571870 A JP 2021571870A JP 2021571870 A JP2021571870 A JP 2021571870A JP WO2020247618 A5 JPWO2020247618 A5 JP WO2020247618A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- taci
- cdr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 29
- 101000795167 Homo sapiens Tumor necrosis factor receptor superfamily member 13B Proteins 0.000 claims 21
- 102100029675 Tumor necrosis factor receptor superfamily member 13B Human genes 0.000 claims 21
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 17
- 229920001184 polypeptide Polymers 0.000 claims 16
- 108090000765 processed proteins & peptides Proteins 0.000 claims 16
- 102000004196 processed proteins & peptides Human genes 0.000 claims 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 210000004962 mammalian cell Anatomy 0.000 claims 8
- 108091033319 polynucleotide Proteins 0.000 claims 7
- 102000040430 polynucleotide Human genes 0.000 claims 7
- 239000002157 polynucleotide Substances 0.000 claims 7
- 208000021161 Plasma cell disease Diseases 0.000 claims 6
- 230000004068 intracellular signaling Effects 0.000 claims 6
- 208000023275 Autoimmune disease Diseases 0.000 claims 5
- 239000012634 fragment Substances 0.000 claims 5
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims 3
- 239000000427 antigen Substances 0.000 claims 3
- 102000036639 antigens Human genes 0.000 claims 3
- 108091007433 antigens Proteins 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 claims 2
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 208000007452 Plasmacytoma Diseases 0.000 claims 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 210000002865 immune cell Anatomy 0.000 claims 2
- 210000004263 induced pluripotent stem cell Anatomy 0.000 claims 2
- 239000003446 ligand Substances 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 102100027207 CD27 antigen Human genes 0.000 claims 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 1
- 102000001493 Cyclophilins Human genes 0.000 claims 1
- 108010068682 Cyclophilins Proteins 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 102100025594 Guided entry of tail-anchored proteins factor CAMLG Human genes 0.000 claims 1
- 208000031220 Hemophilia Diseases 0.000 claims 1
- 208000009292 Hemophilia A Diseases 0.000 claims 1
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims 1
- 101000932902 Homo sapiens Guided entry of tail-anchored proteins factor CAMLG Proteins 0.000 claims 1
- 101000946860 Homo sapiens T-cell surface glycoprotein CD3 epsilon chain Proteins 0.000 claims 1
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 claims 1
- 208000019758 Hypergammaglobulinemia Diseases 0.000 claims 1
- -1 ICOS Proteins 0.000 claims 1
- 206010053869 POEMS syndrome Diseases 0.000 claims 1
- 208000004346 Smoldering Multiple Myeloma Diseases 0.000 claims 1
- 102100035794 T-cell surface glycoprotein CD3 epsilon chain Human genes 0.000 claims 1
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 1
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims 1
- 239000012190 activator Substances 0.000 claims 1
- 229910052791 calcium Inorganic materials 0.000 claims 1
- 239000011575 calcium Substances 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 201000006569 extramedullary plasmacytoma Diseases 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 208000025750 heavy chain disease Diseases 0.000 claims 1
- 210000005260 human cell Anatomy 0.000 claims 1
- 206010020718 hyperplasia Diseases 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 201000009234 osteosclerotic myeloma Diseases 0.000 claims 1
- 208000031223 plasma cell leukemia Diseases 0.000 claims 1
- 210000004180 plasmocyte Anatomy 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 208000010721 smoldering plasma cell myeloma Diseases 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962856998P | 2019-06-04 | 2019-06-04 | |
| US62/856,998 | 2019-06-04 | ||
| US201962907930P | 2019-09-30 | 2019-09-30 | |
| US62/907,930 | 2019-09-30 | ||
| US202063012735P | 2020-04-20 | 2020-04-20 | |
| US63/012,735 | 2020-04-20 | ||
| PCT/US2020/036108 WO2020247618A1 (en) | 2019-06-04 | 2020-06-04 | Antibodies and chimeric antigen receptors that target taci |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022535410A JP2022535410A (ja) | 2022-08-08 |
| JPWO2020247618A5 true JPWO2020247618A5 (enExample) | 2023-06-13 |
| JP7584453B2 JP7584453B2 (ja) | 2024-11-15 |
Family
ID=73652958
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021571870A Active JP7584453B2 (ja) | 2019-06-04 | 2020-06-04 | Ｔａｃｉを標的とする抗体及びキメラ抗原受容体 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20220324964A1 (enExample) |
| EP (1) | EP3980454A4 (enExample) |
| JP (1) | JP7584453B2 (enExample) |
| CN (1) | CN114206919B (enExample) |
| AU (1) | AU2020287626A1 (enExample) |
| CA (1) | CA3139057A1 (enExample) |
| WO (1) | WO2020247618A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022246004A1 (en) * | 2021-05-19 | 2022-11-24 | Celledit Llc | Bi-specific chimeric antigen receptors and genetically engineered immune cells expressing such |
| WO2023178073A2 (en) * | 2022-03-15 | 2023-09-21 | Celledit Llc | Use of antigen presenting cells to enhance car-t cell therapy |
| CN118139890A (zh) * | 2022-09-14 | 2024-06-04 | 荣昌生物制药(烟台)股份有限公司 | 一种taci抗体及其用途 |
| US20260015430A1 (en) * | 2022-11-08 | 2026-01-15 | Agency For Science, Technology And Research | Antigen binding protein specific for transmembrane activator and caml interactor (taci) |
| CN117288933A (zh) * | 2023-09-21 | 2023-12-26 | 桂林医学院附属医院 | 检测car-t细胞杀伤力的方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7083950B2 (en) | 1998-09-25 | 2006-08-01 | Regeneron Pharmaceuticals, Inc. | High affinity fusion proteins and therapeutic and diagnostic methods for use |
| WO2002066516A2 (en) * | 2001-02-20 | 2002-08-29 | Zymogenetics, Inc. | Antibodies that bind both bcma and taci |
| EP1551877A4 (en) | 2002-07-25 | 2006-01-18 | Genentech Inc | TACI ANTIBODIES AND THEIR USE |
| WO2004074511A1 (en) | 2003-02-21 | 2004-09-02 | Garvan Institute Of Medical Research | Diagnosis and treatment of baff-mediated autoimmune diseases and cancer |
| CA2679266A1 (en) | 2007-02-27 | 2008-09-04 | Forerunner Pharma Research Co., Ltd. | Pharmaceutical composition comprising anti-grp78 antibody as active ingredient |
| WO2015128653A2 (en) * | 2014-02-27 | 2015-09-03 | Ucl Business Plc | Ligand |
| CN105384825B (zh) * | 2015-08-11 | 2018-06-01 | 南京传奇生物科技有限公司 | 一种基于单域抗体的双特异性嵌合抗原受体及其应用 |
| WO2017040324A1 (en) * | 2015-08-28 | 2017-03-09 | The Trustees Of The University Of Pennsylvania | Methods and compositions for cells expressing a chimeric intracellular signaling molecule |
| CN110114371A (zh) | 2016-11-11 | 2019-08-09 | 奥托路斯有限公司 | 嵌合抗原受体 |
| CN108490174B (zh) * | 2018-04-18 | 2022-06-24 | 上海尚珞生物医药科技有限公司 | 检测car-t细胞的方法及其应用 |
-
2020
- 2020-06-04 WO PCT/US2020/036108 patent/WO2020247618A1/en not_active Ceased
- 2020-06-04 US US17/616,274 patent/US20220324964A1/en active Pending
- 2020-06-04 JP JP2021571870A patent/JP7584453B2/ja active Active
- 2020-06-04 AU AU2020287626A patent/AU2020287626A1/en active Pending
- 2020-06-04 CA CA3139057A patent/CA3139057A1/en active Pending
- 2020-06-04 CN CN202080054113.3A patent/CN114206919B/zh active Active
- 2020-06-04 EP EP20818549.6A patent/EP3980454A4/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI883026B (zh) | 抗ｄｌｌ３嵌合抗原受體及其用途 | |
| JP6873901B2 (ja) | Ｔｎｆファミリーリガンド三量体を含む抗原結合分子 | |
| CN107428830B (zh) | 单体fc结构域 | |
| JP2017527275A5 (enExample) | ||
| KR20190065318A (ko) | 세포에 의해 발현되는 생물학적 활성을 조절하는 결합 분자 | |
| CA3086653A1 (en) | Tumor necrosis factor (tnf) receptor superfamily (tnfrsf) receptor-activating antibody fusion proteins with fcyr-independent agonistic activity (tnfrsf receptor-activating antibody fusion proteins with fcyr-independ ent agonistic activity; traaffiaa) | |
| JP2019524693A5 (enExample) | ||
| US20240209106A1 (en) | Anti-cd137 antibodies and methods of use | |
| JP2024054284A (ja) | ガンの処置のための結合分子 | |
| AU2025279645A1 (en) | Binding Protein Having H2L2 And HCAB Structures | |
| US20240190983A1 (en) | Novel TNFR2 Binding Molecules | |
| JPWO2020076992A5 (enExample) | ||
| US20240400705A1 (en) | Composition of recombinant antigen binding molecules and method of making and using thereof | |
| JPWO2020247618A5 (enExample) | ||
| WO2024193669A1 (zh) | 抗tnfr2/抗pd-1或ctla-4双特异性抗体及其应用 | |
| CN119894930A (zh) | 一种双特异性抗体及其应用 | |
| WO2024094151A1 (en) | Multi-specific antibody and medical use thereof | |
| RU2023128561A (ru) | Gucy2c-связывающий полипептид и его применение | |
| JP2025539145A (ja) | 抗ｃｄ１３７抗体及びその使用方法 | |
| CN115505045A (zh) | 靶向lag-3和pd-l1的新型双特异抗体及其应用 | |
| HK40110781A (zh) | 一种抗dll3嵌合抗原受体及其用途 | |
| HK40110214A (zh) | 一种抗dll3嵌合抗原受体及其用途 | |
| HK40098926A (zh) | 一种抗dll3嵌合抗原受体及其用途 | |
| CN119768434A (zh) | 一种双特异性抗体及其应用 | |
| Zhu et al. | Dual-Targeting Bispecific Antibodies as New Therapeutic Modalities for Cancer |